stannsoporfin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Nutritional and Metabolic Diseases

Conditions

Nutritional and Metabolic Diseases

Trial Timeline

May 1, 2002 → Feb 1, 2013

NCT ID

NCT02685137

About stannsoporfin

stannsoporfin is a phase 3 stage product being developed by Mallinckrodt Pharmaceuticals for Nutritional and Metabolic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02685137. Target conditions include Nutritional and Metabolic Diseases.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00850993	Phase 2	Terminated	Aug 1, 2008	May 1, 2012	Hyperbilirubinemia, Neonatal
NCT02685137	Phase 3	Completed	May 1, 2002	Feb 1, 2013	Nutritional and Metabolic Diseases

Competing Products

2 competing products in Nutritional and Metabolic Diseases

See all competitors

Product	Company	Stage	Hype Score
rasburicase (SR29142)	Sanofi	Phase 2	51
ClinOleic (Baxter Healthcare, Deerfield, IL, USA)	Baxter	Phase 1	30

Other Products from Mallinckrodt Pharmaceuticals

Lubiprostone + Lubiprostone + LubiprostoneApproved

Lubiprostone + PlaceboPhase 3